What is HC Wainwright's Estimate for Nkarta FY2025 Earnings?

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities researchers at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Nkarta in a research note issued on Thursday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.21) for the year, up from their previous estimate of ($1.29). HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta's Q4 2025 earnings at ($0.27) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at ($0.95) EPS.

A number of other analysts also recently issued reports on NKTX. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. Stifel Nicolaus reduced their price objective on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th. Finally, Needham & Company LLC dropped their target price on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $14.67.

Nkarta Stock Performance

NASDAQ:NKTX traded down $0.02 during trading hours on Monday, reaching $1.75. The stock had a trading volume of 254,607 shares, compared to its average volume of 1,067,120. Nkarta has a 52 week low of $1.31 and a 52 week high of $8.23. The company has a 50 day moving average price of $1.80 and a two-hundred day moving average price of $2.15. The stock has a market capitalization of $124.18 million, a PE ratio of -0.93 and a beta of 0.81.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01.

Hedge Funds Weigh In On Nkarta

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC boosted its holdings in Nkarta by 118.7% during the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after acquiring an additional 852,559 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Nkarta by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company's stock valued at $1,253,000 after acquiring an additional 80,211 shares during the period. AQR Capital Management LLC boosted its holdings in Nkarta by 300.5% during the 1st quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock valued at $1,237,000 after acquiring an additional 504,272 shares during the period. AWM Investment Company Inc. boosted its holdings in Nkarta by 150.0% during the 1st quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company's stock valued at $1,840,000 after acquiring an additional 600,000 shares during the period. Finally, Alyeska Investment Group L.P. boosted its holdings in Nkarta by 54.7% during the 1st quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company's stock valued at $3,800,000 after acquiring an additional 730,260 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.